Mecasermin - Biologic Drug Details

Summary for mecasermin

Tradenames:	1
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	2

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for mecasermin Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for mecasermin Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Ipsen Biopharmaceuticals, Inc.	INCRELEX	mecasermin	Injection	021839		2014-10-28	DrugPatentWatch analysis and company disclosures
Ipsen Biopharmaceuticals, Inc.	INCRELEX	mecasermin	Injection	021839		2015-10-20	DrugPatentWatch analysis and company disclosures
Ipsen Biopharmaceuticals, Inc.	INCRELEX	mecasermin	Injection	021839		2016-05-03	DrugPatentWatch analysis and company disclosures
Insmed Incorporated	IPLEX	mecasermin rinfabate	Injection	021884		2014-10-28	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for mecasermin Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Ipsen Biopharmaceuticals, Inc.	INCRELEX	mecasermin	Injection	021839		2036-12-20	Patent claims search
Ipsen Biopharmaceuticals, Inc.	INCRELEX	mecasermin	Injection	021839		2036-08-10	Patent claims search
Ipsen Biopharmaceuticals, Inc.	INCRELEX	mecasermin	Injection	021839		2038-12-19	Patent claims search
Ipsen Biopharmaceuticals, Inc.	INCRELEX	mecasermin	Injection	021839		2037-11-08	Patent claims search
Ipsen Biopharmaceuticals, Inc.	INCRELEX	mecasermin	Injection	021839		2038-07-09	Patent claims search
Ipsen Biopharmaceuticals, Inc.	INCRELEX	mecasermin	Injection	021839		2038-09-17	Patent claims search

Mecasermin Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are the Market Dynamics for Mecasermin?

Mecasermin (brand name: Increlex) is a recombinant human insulin-like growth factor-1 (IGF-1). Approved by the FDA in 2005 for treating severe primary IGF-1 deficiencies and growth failure in children with open epiphyses, the drug occupies a niche in rare disease therapy. Its market is influenced by its small target population, limited competition, and evolving therapeutic landscape.

Market Size and Growth Drivers

The global biotech market values the IGF-1 deficiency segment at approximately USD 400 million in 2022, projected to grow at a compound annual growth rate (CAGR) of 4.5% through 2030[1].

Key growth factors include:

• Increasing Diagnosis of Growth Disorders: Improved diagnostic techniques, genetic testing, and awareness have led to higher detection rates.

• Limited Treatment Options: Mecasermin remains the primary therapy for severe primary IGF-1 deficiencies in children, with no direct biosimilar competitors approved.

• Expansion into New Indications: Trials exploring mecasermin for conditions like cachexia and certain short stature syndromes could create additional markets.

Competitive Landscape

Currently, no biosimilars for mecasermin have received regulatory approval. Growth hormone therapies (e.g., somatropin) remain the primary alternative, but they lack efficacy in IGF-1 deficiency cases where mecasermin is indicated.

Pricing and Reimbursement

Treatment pricing varies:

• Per-Patient Cost: Estimated USD 20,000–30,000 annually per pediatric patient[2].

• Reimbursement: Typically covered under specialized drug programs, though reimbursement policies vary by country, affecting accessibility.

What Is the Financial Trajectory of Mecasermin?

Revenue Estimates

• Historical Revenue: Pfizer reported approximately USD 150 million in global sales for Increlex in 2008, but sales declined over subsequent years due to limited uptake and competition from off-label growth hormone use[3].

• Current Revenue: Exact figures are proprietary. Industry estimates place current annual sales below USD 50 million globally, primarily driven by select pediatric markets.

Cost Factors

• Manufacturing: High costs associated with recombinant protein production, purification, and cold-chain logistics.

• Regulatory and R&D Expenditure: Significant investments in clinical trials, especially for expanding indications, can reach USD 100+ million per new trial phase.

Future Revenue Projections

Several factors could influence future revenue:

• Expanded Indications: Approval for additional conditions could diversify revenue sources.

• Market Penetration: Increased awareness and diagnostic rates could expand patient numbers.

• Pricing Trends: Potential for price reductions with market expansion or biosimilar development.

• Competitive Entry: Introduction of biosimilars or alternative therapies could pressure prices and volumes.

Given the current market size and limited competition, the revenue trajectory remains modest, with growth contingent on regulatory approvals and successful market access strategies.

Key Market Challenges and Opportunities

Challenges

• Small patient population limits sales volume.

• High production costs restrict profit margins.

• Limited awareness among physicians may constrain adoption.

• Regulatory hurdles for expanding indications.

Opportunities

• Development of biosimilars to reduce prices.

• Expanding to adult indications, such as cachexia.

• Improving awareness and diagnostic mechanisms.

Key Takeaways

• Mecasermin operates in a niche market for severe IGF-1 deficiency, with limited current revenues but potential for growth through indication expansion.

• Market size remains below USD 400 million globally, with annual sales under USD 50 million recently.

• High manufacturing costs, pricing pressures, and competition from growth hormone therapies impact financial performance.

• Strategic focus on broadening indications and market access could improve the drug’s financial trajectory.

• Biosimilar entry risks further price erosion but may also create alternative access channels.

FAQs

1. What conditions can mecasermin treat besides primary IGF-1 deficiency?
Currently, approved indications are limited to severe primary IGF-1 deficiency in children. Investigational uses include cachexia and short stature syndromes, but these are not yet approved.

2. Are biosimilars expected for mecasermin soon?
No biosimilars are approved as of 2023. Given the complexity of recombinant IGF-1 and market size, biosimilar development faces scientific and economic hurdles.

3. How does mecasermin compare to growth hormone therapies?
Mecasermin bypasses the growth hormone pathway, directly supplementing IGF-1. It is used when growth hormone therapy is ineffective or contraindicated.

4. Which markets have the highest sales potential for mecasermin?
Developed markets like the US, Europe, and Japan lead in diagnosis and treatment, but growth is limited by cost and awareness. Emerging markets may represent future growth if reimbursement barriers decrease.

5. What are the regulatory trends affecting mecasermin?
Revisions focus on expanding indications, improving manufacturing processes, and reducing costs. Regulatory agencies emphasize safety monitoring and long-term efficacy data for rare disease treatments.

---

Sources
[1] MarketWatch, "Global IGF-1 Deficiency Market," 2022.
[2] Pharma Price Index, "Increlex Pricing," 2022.
[3] Pfizer Annual Report, 2008.